Neuro-Bio Gets $3.2M in Funding from U.S. Investor to Develop New Approach to Alzheimer’s

Neuro-Bio Gets $3.2M in Funding from U.S. Investor to Develop New Approach to Alzheimer’s
British pharmaceutical company Neuro-Bio has received $3.2 million in financing from Los Angeles-based Kairos Ventures to continue developing a diagnostic tool for early detection of Alzheimer’s disease. This tool stems from a novel approach to Alzheimer’s pioneered in 2013 by Neuro-Bio's founder and CEO, Susan Greenfield, and her team at Oxford University. Resulting from 40 years of basic research, this approach focuses on a previously unidentified process that might be behind the continuing cycle of cell death that defines the neurodegenerative process. Neuro-Bio wants to see if drugs can stop the activation of these brain mechanisms, and if these processes can be tracked with blood biomarkers. “We are delighted to have secured this Series A investment to support the continued growth of our company from start-up to small enterprise," Greenfield said in a press release. "The investment from Kairos is the recognition of our fresh approach as well as the expertise of our team. This investment will increase the possibility of discovery of a novel disruptive treatment that is much needed to improve outcomes for patients with Alzheimer's." The last few months have seen the demise of several anti-Alzheimer drug candidates. Neuro-Bio will now be able to open up a new direction in the search for an eff
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *